• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
172894 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
) o8 r( L; |( b1 s
  _0 x& ?/ M* x, w' u
; l  E* s% c9 s5 eSub-category:
: h5 D1 f; S! j' r5 ]% a% _Molecular Targets
/ a, i3 [$ [* ^& ^2 v6 w9 I
) V- C) }* T7 A6 o3 ~! W( Z9 S; v7 @" L
Category:3 Z6 G; }/ I# Q3 _% ^
Tumor Biology
7 P& B/ f! R1 W! H3 L- L
3 z2 n3 i& V, g# f1 H, q( U9 y- t4 f
Meeting:+ H; {- e3 m( R
2011 ASCO Annual Meeting 0 J# p# [' E5 `2 F, p
1 P, d3 {" _1 t5 y" o- j- O5 g4 h

& B. R8 c" Z) ~' e& l0 R/ fSession Type and Session Title:" |; w3 i+ N1 ]' r
Poster Discussion Session, Tumor Biology
3 `/ y  K7 y# h' O3 K
3 f$ `/ C% N* \* E# J
/ [* v: G' Z: X# ~3 e4 L" r5 FAbstract No:
9 X& K5 c% `- U! m* R8 R10517 # d$ e9 s3 k5 Q3 K9 v  {, F
$ y7 _* Y9 _9 u* }
* N# `. P# ]  S  U/ i
Citation:
$ [. f8 l1 d8 N* HJ Clin Oncol 29: 2011 (suppl; abstr 10517)
  {* q0 z  k+ b" F) |% @8 p0 e4 l3 {. y. C- i
( I: A6 D  G- K9 C! D7 F8 p
Author(s):
; E% h$ X% V9 ~9 x2 rJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 8 W- e; B+ M3 O: N" d6 B. j
0 y! M6 h% z- C6 N+ k
$ ~% F# U3 w. h* {( W$ H
( W- d( q! f3 t' _& |
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 i- G$ y5 D8 q, Z+ c% v7 u3 ?- c. S8 p  M- \8 s: x! w
Abstract Disclosures
6 r1 g" H, G" n4 g! w' b
5 g0 ~# n. i/ k  c- M! pAbstract:6 m! X: s, \8 W6 T) O

+ G) R+ t; z7 |5 ^
+ L, b4 e" O- h+ ]2 E0 F2 zBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; ], Y3 `! o( E; h6 ?' }

& q$ w) m; o: L$ E* k( y - c3 b9 z' U; T; ?" F% o. K
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
# c9 b& `& R# \4 ?# }& g' q" h0 P) p没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
7 X3 x! s; O9 o" Q' G6 Z& Z* C
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
4 \0 l* m9 G3 ^+ K; k" h1 e易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
+ a4 {3 t3 W) BALK一个指标医院要900多 ...

  Y( x) a) J* H" {4 {% T平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
& j' t: {2 a! V! g
/ k2 U) E7 ]: e3 D* a现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表